Nemonoxacin
Names | |
---|---|
Preferred IUPAC name
7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | |
Identifiers | |
3D model (
JSmol ) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
IUPHAR/BPS |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H25N3O4 | |
Molar mass | 371.437 g·mol−1 |
Pharmacology | |
J01MB08 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Nemonoxacin is a non-fluorinated
acute bacterial skin and skin-structure infections (ABSSSI).[5]
Nemonoxacin has a broad spectrum of activity against
C.difficile isolates that are resistant to other quinolones,[9] and is more potent than levofloxacin or moxifloxacin.[10]
References
- S2CID 34452344.
- ^ "TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan". 16 December 2015.
- ^ Biotechnology T. "TaiGen Biotechnology Out-Licenses Taigexyn® (Nemonoxacin) to Productos Científicos for the Latin American Market" (Press release).
- ^ "A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP - Full Text View - ClinicalTrials.gov". 22 October 2021.
- ^ "FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin". 23 December 2013.
- PMID 20065058.
- PMID 19738018.
- PMID 20660689.
- PMID 22508299.
- PMID 23587953.